Suitable for Dot, IM, IHC-Fr, IHC-P, ELISA, WB, ICC/IF. Cited in 6 publications.
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application Dot | Reactivity Expected | Dilution info - | Notes - |
Application IM | Reactivity Expected | Dilution info - | Notes - |
Application IHC-Fr | Reactivity Expected | Dilution info 1/1000 - 1/5000 | Notes - |
Application IHC-P | Reactivity Expected | Dilution info 1/1000 - 1/5000 | Notes - |
Application ELISA | Reactivity Reacts | Dilution info 1/20000 - 1/100000 | Notes - |
Application WB | Reactivity Expected | Dilution info 1/2000 - 1/10000 | Notes - |
Application ICC/IF | Reactivity Expected | Dilution info 1/1000 - 1/5000 | Notes - |
Ig gamma 1 chain C region, Ig gamma 3 chain C region, Ig gamma 4 chain C region, Ig gamma-2 chain C region, Immunoglobin heavy constant gamma 1, Immunoglobulin G
Suitable for Dot, IM, IHC-Fr, IHC-P, ELISA, WB, ICC/IF. Cited in 6 publications.
Preservative: 0.01% Sodium azide
Constituents: 1% BSA, 0.88% Sodium chloride, 0.424% Potassium phosphate solution
Anti-Sheep IgG antibody was prepared from monospecific antiserum by immunoaffinity chromatography using Sheep IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
ELISA results of ab6899 against Sheep IgG. Each well was coated in duplicate with 1.0 µg of Sheep IgG. The starting dilution of antibody was 5 µg/ml and the X-axis represents the Log10 of a 3-fold dilution. This titration is a 4-parameter curve fit where the IC50 is defined as the titer of the antibody. Assay performed using Streptavidin HRP conjugate and TMB substrate.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com